Redeye views InfraCom’s Q2 2025 results as mixed, with a declining top line contrasted by rising EBI...
Redeye updates its estimates and valuation following Navigo’s Q2 2025 report.
Redeye lowers its estimates on the back of I-Tech’s second quarter, which showed a surprising slowdo...
* Net acquistions in H2'25 * Buy-backs supportive for the share * 2025e P/CEPS 11x vs.
Redeye provides an in-depth review of Acarix’s Q2 report and related events during and after the qua...
* Weaker Q2 due to natural quarterly variations * Cut '25e-'27e EBIT by 12-13% * Demand intact, rebo...
* Q2 sales +3% and EBITDA +4% vs. ABGSCe * We raise EBITDA by 1-4% and EBIT by 4-8% for '26e-'27e * ...
* Q2 NAV in line with ABGSCe * Key highlights: Safe Life transaction and buybacks * Discount still w...
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye comments on Medivir’s Q2 report. The quarter was somewhat uneventful, but the company has mad...
* Sales SEK 6.5m, EBIT SEK -16m (vs. ABGSCe 11m and -12m) * No machine deliveries in the quarter (in...
* Sales +4% and adj. EBIT -47% vs ABGSCe * Weak demand in consulting and recruitment market * Consen...
Solteq’s Q2 result was below our expectations. Retail & Commerce was decent, while Utilities remaine...
Nokian Panimo delivered a solid debut performance that met expectations despite challenging weather ...
Redeye comments on I-Tech’s Q2 figures that missed our expectations, driven by weaker sales.
Redeye notes that Avtech delivered another solid quarter, with net sales growing 37% y/y, in line wi...
Redeye notes that InfraCom’s Q2 2025 report was below expectations for sales (-9%) and EBITDA (-12%)...
* Q2: 3% sales growth, 1% adj. EBIT margin * '25e-'27e adj.
Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the com...
Redeye updates its estimates and valuation following the Q2 2025 report from Catella.
